Cabometyx (cabozantinib) — United Healthcare
Ewing Sarcoma (including mesenchymal chondrosarcoma)
Initial criteria
- One of the following diagnoses: Osteosarcoma OR Ewing Sarcoma (including mesenchymal chondrosarcoma)
- Disease is one of the following: relapsed/refractory OR metastatic
- Used as second-line therapy
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Cabometyx therapy
Approval duration
12 months